Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06562270 · ClinicalTrials.gov registry record
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
A clinical trial of Alopecia Areata, sponsored by CorEvitas.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT06562270 is a study of Alopecia Areata that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 1,500 participants, below the 1,898-participant average among 26 other Alopecia Areata trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06562270, a study of Alopecia Areata, is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines/regulations in the country where the participating registry site is located.
Conditions Studied
Study Locations (1)
Massachusetts
- CorEvitas, LLC - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2024-03-07 |
| Est. Completion | 2099-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06562270
The ClinicalTrials.gov registry entry for NCT06562270 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,898-participant average among 26 other Alopecia Areata trials with a reported enrollment target (21% lower). The listed sponsor is CorEvitas, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 0 interventions.
NCT06562270 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06562270 about?
NCT06562270 is a clinical study titled "CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry". Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to pat...
What is the current status of trial NCT06562270?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2024-03-07. Estimated completion is 2099-12-31.
What conditions does trial NCT06562270 study?
This clinical trial studies the following conditions: Alopecia Areata.
Who is sponsoring clinical trial NCT06562270?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06562270 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Intralesional Cyclosporine for Alopecia Areata
RECRUITING · Early Phase 1
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.